Genprex (GNPX) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Genprex (NASDAQ:GNPX) issued its quarterly earnings results on Tuesday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02), Yahoo Finance reports.
Shares of GNPX traded down $0.03 during mid-day trading on Wednesday, hitting $1.32. The company’s stock had a trading volume of 86 shares, compared to its average volume of 26,484. Genprex has a 52-week low of $1.26 and a 52-week high of $19.45.
Separately, Maxim Group initiated coverage on shares of Genprex in a report on Friday, September 14th. They set a “buy” rating and a $5.00 price target on the stock.
Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.
Featured Story: How Investors Use a Balance Sheet
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.